Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Ford Credit Floorplan Master Owner Trust a Capital Raise
Ford Credit Floorplan Master Owner Trust A entered into definitive transaction documents, including an Indenture Supplement and Account Control Agreement, for the issuance of Series 2026-3 asset-backed notes. The filing formalizes the legal structure for the trust's latest issuance of securities backed by dealer floorplan receivables.
Barrel Energy Signs $20M M&A Deal with Maine Bio-Fuel, Inc.
Barrel Energy Inc. has signed a letter of intent to acquire a 51% controlling interest in Maine Bio-Fuel, Inc. (doing business as Maine Standard Biofuels) for $20 million in cash and stock. The closing is contingent upon Barrel completing a separate business combination with a company listed on a national exchange (Nasdaq or NYSE) and securing a qualifying credit facility to fund the cash portion of the deal.
Tcgx Acquisition Signs $361M M&A Deal with TriGemX Bio, Inc.
TCGX Acquisition Corp. (SPAC) has entered into a definitive business combination agreement with TriGemX Bio, Inc. at a pre-money equity value of $361 million. The transaction includes a concurrent $160 million PIPE financing and is expected to provide approximately $246 million in gross proceeds to fund Phase 3 development of elismetrep for migraine. Upon closing, expected in Q1 2027, the combined company will be named TriGemX Bio, Inc. and trade on Nasdaq under the ticker TGEM.
Veradermics announced positive topline results from its Phase 3 '304' clinical trial of VDPHL01 for male pattern hair loss, meeting all primary and secondary endpoints with high statistical significance. The study demonstrated robust increases in hair count and rapid onset of activity as early as Month 2, with a favorable safety profile and no treatment-related serious adverse events. These results, combined with prior Phase 2/3 data, support a potential FDA submission for the first non-hormonal oral treatment for pattern hair loss.
Data I Signs $13.2M M&A Deal with V-TEK and A&J Programming
Data I/O Corporation has entered into a definitive agreement to acquire V-TEK and A&J Programming. To fund the transaction and provide working capital, the company also announced a $13.25 million private placement of convertible subordinated debentures and common shares at a conversion price of $2.68 per share.
Cardinal Infrastructure Group Signs $358M M&A Deal with Hughes Brothers Construction Inc.
Cardinal Infrastructure Group entered into a definitive agreement to acquire Hughes Brothers Construction Inc., a Central Florida heavy civil and site development contractor, for an aggregate purchase price of $357.5 million. The consideration consists of $214.5 million in cash and $143.0 million in Class A common stock, with an additional earn-out potential of up to $162.5 million based on future EBITDA performance. The acquisition establishes a scaled platform for Cardinal in the fast-growing Florida market and is expected to close in the fourth quarter of 2026.
Value
$358M
Counterparty
Hughes Brothers Construction Inc.
“We are excited to welcome Hughes Brothers to Cardinal as we take another important step in our strategy to build the Southeast’s premier site development platform by moving into the fast-growing Central Florida market. Hughes Brothers is an exceptional founder-led business that culturally aligns with what we’re building. They bring an experienced team, both in terms of field personnel and corporate leadership, longstanding customer relationships, h”
Jeremy Spivey, CEO of Cardinal Infrastructure Group
OS Therapies announced the initial closing of a warrant exercise inducement and exchange offer, raising $7.2 million in gross proceeds from seven accredited investors. Participating holders exercised warrants at a reduced price of $1.30 per share in exchange for new warrants to purchase an equal number of shares at $1.40. The proceeds will fund regulatory filings and commercial preparation for Herlystic™ in the U.S., U.K., EU, and Australia.
Dogwood Therapeutics entered into a subscription agreement to sell 4,098,360 shares of common stock to its largest shareholder, Sealbond Limited (a subsidiary of CK Life Sciences), in a $5 million private placement. The proceeds will be used to fund Phase 3 preparatory activities for Halneuron® and extend the company's operational runway through March 2027.
Atkore Inc. completed its merger with Prysmian S.p.A., with Atkore becoming a wholly owned subsidiary of Prysmian. Shareholders of Atkore received $95.00 in cash per share. In connection with the closing, Atkore terminated its existing credit facilities and redeemed $400 million of its 4.25% Senior Notes due 2031.
Fuller H B Signs $1.4B M&A Deal with Ancora Holdings Group LLC
H.B. Fuller's Board of Directors unanimously rejected a second unsolicited, non-binding proposal from Ancora Holdings Group LLC to acquire the Company's Building Adhesive Solutions (BAS) business for $1.2 billion to $1.4 billion. The Board determined the offer undervalued the segment and lacked sufficient detail, though the Company will conduct a market check for select market segments and product lines by year-end 2026 to evaluate potential divestitures for deleveraging.
Mks Divestiture to TTM Technologies, Inc. for $650M
MKS Inc. has entered into a definitive agreement to sell its Ophir Optics business to TTM Technologies, Inc. for $650 million in cash. The transaction, which represents an 18x multiple of projected 2026 Adjusted EBITDA, is expected to close in the second quarter of 2027 and aims to strengthen MKS's balance sheet while focusing on its core semiconductor and electronics markets.
Ttm Technologies Signs $650M M&A Deal with MKS Inc.
TTM Technologies has entered into a definitive agreement to acquire the Ophir Optics business from MKS Inc. for approximately $650 million in an all-cash transaction. The acquisition adds high-precision infrared thermal imaging and laser optics capabilities to TTM's defense and industrial portfolio and is expected to close in the second quarter of 2027.
Value
$650M
Counterparty
MKS Inc.
“We are excited to announce our planned acquisition of the Ophir Optics business as another important step toward enhancing our long-term growth strategy by expanding our portfolio with mission-critical optical solutions for land, air, maritime, and unmanned platforms and our industrial portfolio.”
ArriVent BioPharma announced the publication of Phase 1b results for firmonertinib in the journal Cancer Cell, focusing on patients with advanced EGFR PACC-mutant non-small cell lung cancer (NSCLC). The data showed a confirmed overall response rate (ORR) of 68% at the 240 mg dose and a median progression-free survival of 16.0 months, supporting the ongoing global Phase 3 ALPACCA trial.
Silence Therapeutics has entered into a definitive agreement to be acquired by Merck KGaA, Darmstadt, Germany for approximately $1.3 billion in cash. Under the terms of the deal, Silence shareholders will receive $20.00 per ADS, representing a 130% premium to the company's recent closing price. The acquisition aims to strengthen Merck KGaA's specialty and rare disease pipeline, specifically incorporating Silence's Phase 2 siRNA candidate, Divesiran.
Value
$1.3B
Counterparty
Merck KGaA, Darmstadt, Germany
“We are pleased to have reached this agreement with Merck KGaA, Darmstadt, Germany, which is the result of a competitive sale process and delivers significant, immediate and certain value to our shareholders.”
Iain Ross, Interim Principal Executive Officer and Chairman of the Silence Board
“The planned acquisition of Silence Therapeutics will strengthen our capabilities to serve patients with targeted specialty and rare diseases.”
Kai Beckmann, Chairman of the Executive Board and Group CEO of Merck KGaA, Darmstadt, Germany
Super League stockholders approved a strategic investment from Metaplanet, Inc. involving the contribution of 2,100 Bitcoin and $2.5 million in cash. Upon closing, the company will be renamed Superplanet, Inc. and issue 44,859,400 shares of common stock at $3.00 per share, establishing a Bitcoin-based treasury platform.
Value
$135M
Counterparty
Metaplanet Holdings, Inc.
“I’m deeply grateful to our stockholders for their support. Their approval brings us one step closer to redefining what this company can become. If the transaction closes, we would no longer be defined solely by our current scale. Alongside an operating business that continues to serve many of the world’s most recognizable brands, we would have a treasury seeded with 2,100 Bitcoin and the potential to build a significant position over time.”
Matt Edelman, Chairman, Chief Executive Officer and President of Super League
Centrus Energy Signs $116M M&A Deal with Westerman Holdings, LLC
Centrus Energy Corp. acquired 100% of Westerman Holdings, LLC, a U.S. equipment manufacturing and engineering firm, for approximately $116 million in a mix of cash and stock. The acquisition brings a key supplier of centrifuge components in-house to secure Centrus' supply chain and diversify its revenue base into non-nuclear industrial sectors. Westerman will operate as a wholly owned subsidiary, and its CEO Jacob Garrett will transition to President of the unit and Vice President of Centrus.
Silgan Holdings Signs $3.4B M&A Deal with Trivium Packaging B.V.
Silgan Holdings announced a transformational deal to combine its Metal Containers and flat cap closures businesses with Trivium Packaging B.V. to create a new $7.3 billion partnership called Silgan Metal Containers and Closures (Silgan MCC). Silgan will retain a 60% controlling interest in the partnership while receiving $2.3 billion in cash proceeds, with the acquisition of Trivium valued at an enterprise value of approximately $3.4 billion.
Value
$3.4B
Counterparty
Trivium Packaging B.V.
“This strategic portfolio acceleration reflects our commitment to value creation through deliberate portfolio construction and strategic capital deployment, enabled by the strength of our businesses and our exceptional teams.”
Adam Greenlee, President and Chief Executive Officer
Marker Therapeutics Wins $2.6M Contract from Food & Drug Administration
Marker Therapeutics was awarded a $2.6 million grant from the FDA's Orphan Products Clinical Trials program to advance its lead MAR-T cell therapy, MT-601, for pancreatic cancer. The non-dilutive funding will support a Phase 1 clinical study in patients with locally advanced unresectable pancreatic cancer. Marker was one of only six recipients selected from 66 applications in fiscal year 2026.
Disc Medicine announced positive topline results from its pivotal Phase 3 APOLLO trial of bitopertin in patients with erythropoietic protoporphyria (EPP). The trial met all primary and secondary endpoints, including a 41.4% reduction in whole-blood PPIX and a significant increase in pain-free light tolerance, with an NDA resubmission planned by the end of 2026.
Term
6 months
“Today represents a potential breakthrough in the science and treatment of EPP. We could not have hoped for a better outcome, and we are grateful to the patients, caregivers, and physicians who have partnered with us throughout the clinical development of bitopertin.”
John Quisel, J.D., Ph.D., President and Chief Executive Officer
“These results are compelling evidence of the clinical benefit of a mechanism aimed at reducing the production of PPIX, the fundamental cause of disease. It has been an incredible journey from establishing the original hypothesis of targeting heme synthesis in cellular models to seeing that biology translate into the clear and meaningful clinical effects from APOLLO.”
EyePoint announced topline results from LUCIA, its second pivotal Phase 3 clinical trial of DURAVYU for wet age-related macular degeneration (wet AMD). The trial failed to meet its primary endpoint of statistical non-inferiority in mean change in best corrected visual acuity (BCVA) compared to the aflibercept control, although it did meet secondary endpoints related to treatment burden reduction and safety.
Barnwell Industries M&A Deal with local Canadian corporation
Barnwell Industries provided a status update and Q&A regarding its previously announced agreement to sell its Canadian oil and natural gas business for C$9 million. The consideration includes C$4 million in cash and a 5% gross overriding royalty valued at C$5 million, which the buyer has an option to repurchase for C$5 million in the future.
Transocean Wins $550M Contract from undisclosed operator
Transocean Ltd. secured two ultra-deepwater drillship contracts in the U.S. Gulf of Mexico totaling approximately $550 million in firm backlog. The Deepwater Proteus was awarded a 700-day, ten-well campaign valued at $325 million, while the Deepwater Conqueror received a 450-day, five-well award valued at $225 million.
reAlpha Tech Corp. filed an amendment to its previous 8-K to provide updated audited financial statements for InstaMortgage Inc., which it acquired on August 19, 2026. This filing specifically corrects an inadvertent reference to government auditing standards in the auditor's report and provides the necessary financial exhibits required for the completed merger.
OpenWorld, Inc. has entered into a definitive merger agreement to acquire Blocksight Holdings Co., an AI agent developer for real-world asset tokenization. The acquisition will be settled via the issuance of 641,924 shares of OpenWorld common stock, representing 4% of the company's post-merger fully diluted capitalization. Blocksight's AI agents will be integrated into the OpenWorld Enterprise platform to automate deal structuring and reporting for over $1.1 billion in recently announced tokenized financing programs.
Archimedes Tech SPAC Partners II M&A Deal with Forge Nano, Inc.
Archimedes Tech SPAC Partners II Co. (ATII) announced that its shareholders approved the previously announced business combination with Forge Nano, Inc. at an extraordinary general meeting. The deal is expected to close in the coming days, after which the combined company will operate as Forge Nano Holdings, Inc. and trade on Nasdaq under the ticker symbol 'NANO'.
Powerus M&A Deal with Autonomous Power Corporation
Powerus Corporation filed an amendment to its previous 8-K to provide required financial statements and pro forma information following its completed acquisition of Autonomous Power Corporation (Legacy Powerus). The acquisition was completed on October 1, 2026, pursuant to a merger agreement originally dated March 8, 2026.
DataMeds AI Licensing Deal with REBOOT Health AI, Inc. Worth $2M
DataMeds AI, Inc. entered into an exclusive intellectual property license agreement with REBOOT Health AI to use its AI platform for DataMeds' GLP-1 weight management business. As consideration, DataMeds will issue 666,667 shares of common stock with a guaranteed minimum value of $2 million after 180 days, plus a revenue-sharing arrangement. The company also disclosed it remains below Nasdaq's minimum stockholders' equity requirement for continued listing.
Mobix Labs M&A Deal with Special Project Delivery, Inc.
Mobix Labs provided a status update on its pending acquisition of Special Project Delivery (SPD) and announced that SPD has entered into a definitive agreement to acquire Winner Water Services. The transactions are part of Mobix Labs' 'National Security Matters' initiative to expand into the rare earths and critical minerals market.
Apollo Commercial Real Estate Finance Nasdaq/NYSE Compliance Notice
Apollo Commercial Real Estate Finance, Inc. announced it will voluntarily delist its common stock from the NYSE on or about October 27, 2026, with the last day of trading expected to be November 6, 2026. This action is part of the company's Plan of Complete Liquidation and Dissolution, which involves transferring remaining assets to a liquidating trust and deregistering with the SEC. Following the transfer, stockholders will receive non-transferable beneficial interests in the trust on a one-for-one basis.
Iambic Therapeutics, Inc. filed an amended and restated certificate of incorporation and adopted restated bylaws in connection with the completion of its initial public offering (IPO). The filing formalizes the company's corporate governance structure as it transitions to a publicly traded entity on the Nasdaq Stock Market.